Establishment and validation of patient derived tumor cell model in mucosal melanoma of head and neck

doi:10.19438/j.cjoms.2017.05.002

Abstract

Abstract: PURPOSE: To establish and validate patient derived tumor cell (PDC) model from mucosal melanoma of head and neck (HNMM). METHODS: Tumor cells derived from xenografted tumor tissue of patients with mucosal melanoma of head and neck were validated by immunofluorescence staining. Patient derived tumor cells were injected subcutaneously into nude mice. Tumor tissues originated from PDC were compared to tissue from primary tumors by H-E and immunochemistry staining. RESULTS: Immunofluorescence signal of HMB-45 and Melan-A expressed on membrane and cytoplasm of patient derived tumor cell. Patient derived tumor cell could form subcutaneous tumor in nude mice. The histology was similar between subcutaneous tumor and primary tumor under H-E and immunochemistry staining. CONCLUSIONS: Patient derived tumor cell model can be established from mucosal melanoma of head and neck and be used as a validated preclinical model for drug screening.

Key words: Head and neck, Mucosal melanoma, PDC model, Immunofluorescence staining, Subcutaneous tumor

CLC Number:

R739.5

HAN Yong, SHI Chao-ji, ZHOU Rong, TAO Wen-jie, HONG Duo, LI Jiang, SUN Shu-yang, ZHANG Zhi-yuan.. Establishment and validation of patient derived tumor cell model in mucosal melanoma of head and neck[J]. China Journal of Oral and Maxillofacial Surgery, 2017, 15(5): 388-391.

References

[1] López F, Rodrigo JP, Cardesa A, et al. Update on primary head and neck mucosal melanoma[J]. Head Neck, 2016, 38(1): 147-155.
[2] Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis [J]. Int J Cancer, 2014, 134(12): 2961-2971.
[3] Tanaka N, Mimura M, Ogi K, et al. Primary malignant melanoma of the oral cavity: assessment of outcome from the clinical records of 35 patients[J]. Int J Oral Maxillofac Surg, 2004, 33(8): 761-765.
[4] Tacastacas JD, Bray J, Cohen YK, et al. Update on primary mucosal melanoma[J]. J Am Acad Dermatol, 2014, 71(2): 366-375.
[5] Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma[J]. JAMA, 2011, 305(22): 2327-2334.
[6] Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma [J]. Clin Cancer Res, 2011, 17(7): 1684-1691.
[7] Lian B, Cui CL, Zhou L, et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients [J]. Ann Oncol, 2017, 28(4): 868-873.
[8] Hicks MJ, Flaitz CM. Oral mucosal melanoma: epidemiology and pathobiology [J]. Oral Oncol, 2000, 36(2): 152-169.
[9] Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification [J]. J Clin Oncol, 2011, 29(21): 2904-2909.
[10] Chang KW, Lin SC, Chao SY, et al. Establishment and characterization of an oral melanoma cell line (ME)[J]. Oral Oncol, 2001, 37(3): 301-307.
[11] Lourenco SV, Bologna SB, Hsieh R, et al. Establishment and characterization of an oral mucosal melanoma cell line (MEMO) derived from a longstanding primary oral melanoma [J]. Am J Dermatopathol, 2013, 35(2): 248-251.
[12] Selvan SR, Carbonell DJ, Fowler AW, et al. Establishment of stable cell lines for personalized melanoma cell vaccine [J]. Melanoma Res, 2010, 20(4): 280-292.
[13] Bruna A, Rueda OM, Greenwood W, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds[J]. Cell, 2016, 167(1): 260-274.e222.
[14] Gao Q, Wang ZC, Duan M, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents [J]. Gastroenterology, 2017, 152(1): 232-242.e234.
[15] Arena S, Siravegna G, Mussolin B, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations [J]. Sci Transl Med, 2016, 8(324): 324ra314.
[16] Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery [J]. Nat Rev Drug Discov, 2009, 8(10): 806-823.
[17] Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy [J]. Trends Biotechnol, 2013, 31(6): 347-354.
[18] Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer [J]. Science, 2014, 346(6216): 1480-1486.